Lee-Jen Wei
#20,775
Most Influential Person Now
American biostatistician
Lee-Jen Wei's AcademicInfluence.com Rankings
Lee-Jen Weimathematics Degrees
Mathematics
#3273
World Rank
#4866
Historical Rank
#1223
USA Rank
Statistics
#315
World Rank
#377
Historical Rank
#107
USA Rank
Measure Theory
#2657
World Rank
#3177
Historical Rank
#765
USA Rank
Download Badge
Mathematics
Lee-Jen Wei's Degrees
- Bachelors Mathematics National Taiwan University
Similar Degrees You Can Earn
Why Is Lee-Jen Wei Influential?
(Suggest an Edit or Addition)According to Wikipedia, Lee-Jen Wei is a Taiwanese-American professor of biostatistics at Harvard University. Career He was graduated from Fu Jen Catholic University's Mathematics Department in 1970. He obtained his PhD from the University of Wisconsin–Madison in 1975. He has been a tenured Professor of Biostatistics at Harvard University since 1991 and was the co-director of the Bioinformatics Core at the Harvard School of Public Health from 2003 to 2007. From 2003 to 2004, he served as the acting chair of the Department of Biostatistics at Harvard University. Under his supervision, the department successfully converted the doctor of science degree program in biostatistics to a conventional Ph.D. program at the Harvard Graduate School. This was an important accomplishment since the department had tried this conversion for more than 20 years without success.
Lee-Jen Wei's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Checking the Cox model with cumulative sums of martingale-based residuals (1993) (1373)
- Remdesivir for the Treatment of Covid-19 - Preliminary Report. (2020) (1094)
- Cox-Type Regression Analysis for Large Numbers of Small Groups of Correlated Failure Time Observations (1992) (709)
- Pooled association tests for rare variants in exon-resequencing studies. (2010) (561)
- Analysis of transformation models with censored data (1995) (467)
- Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. (2014) (426)
- dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data (2004) (412)
- Rank-based inference for the accelerated failure time model (2003) (400)
- A resampling method based on pivotal estimating functions (1994) (304)
- Pooled Association Tests for Rare Variants in Exon-Resequencing Studies (2010) (291)
- A simple resampling method by perturbing the minimand (2001) (269)
- Combining dependent tests with incomplete repeated measurements (1985) (228)
- Loss of Heterozygosity and Its Correlation with Expression Profiles in Subclasses of Invasive Breast Cancers (2004) (205)
- Accelerated failure time models for counting processes (1998) (176)
- Maternal Toxicity With Continuous Nevirapine in Pregnancy: Results From PACTG 1022 (2004) (173)
- Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study. (2015) (171)
- Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies. (2015) (160)
- Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio (2017) (155)
- Predicting Survival Probabilities with Semiparametric Transformation Models (1997) (127)
- Restricted Mean Survival Time as a Measure to Interpret Clinical Trial Results. (2017) (116)
- Comparing two failure time distributions in the presence of dependent censoring (1996) (111)
- Semiparametric regression analysis for clustered failure time data (2000) (95)
- Model evaluation based on the sampling distribution of estimated absolute prediction error (2007) (85)
- Linear Regression Analysis for Multivariate Failure Time Observations (1992) (81)
- Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study (2012) (74)
- Prevalence of Metabolic Syndrome and Its Relation to Body Composition in a Chinese Rural Population (2006) (73)
- Regression Parameter Estimation from Panel Counts (2003) (71)
- Linear Regression Analysis for Highly Stratified Failure Time Data (1993) (68)
- Prolylcarboxypeptidase gene, chronic hypertension, and risk of preeclampsia. (2006) (67)
- Inferences for a semiparametric model with panel data (2000) (65)
- Semiparametric Box–Cox power transformation models for censored survival observations (2005) (61)
- Efficiency of two sample tests via the restricted mean survival time for analyzing event time observations (2018) (59)
- Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection. (2005) (45)
- Using the Restricted Mean Survival Time Difference as an Alternative to the Hazard Ratio for Analyzing Clinical Cardiovascular Studies. (2019) (42)
- Treatment selections using risk-benefit profiles based on data from comparative randomized clinical trials with multiple endpoints. (2015) (39)
- A predictive enrichment procedure to identify potential responders to a new therapy for randomized, comparative controlled clinical studies (2016) (39)
- Quantile Regression for Correlated Observations (2004) (35)
- On the covariate-adjusted estimation for an overall treatment difference with data from a randomized comparative clinical trial. (2012) (35)
- How to Quantify and Interpret Treatment Effects in Comparative Clinical Studies of COVID-19 (2020) (34)
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer’s Disease (2018) (33)
- Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy. (2020) (30)
- Applying Evidence-Based Medicine to Shared Decision Making: Value of Restricted MeanSurvival Time. (2019) (24)
- Evaluating Treatment Effect Based on Duration of Response for a Comparative Oncology Study (2018) (23)
- Cross-Study Analysis of the Relative Efficacies of Oral Antiviral Therapies for Chronic Hepatitis B Infection in Nucleoside-Naive Patients (2007) (23)
- Analysis of incomplete repeated measurements with dependent censoring times (1998) (23)
- The Highest Confidence Density Region and Its Usage for Joint Inferences about Constrained Parameters (2011) (21)
- Utility of Restricted Mean Survival Time Analysis for Heart Failure Clinical Trial Evaluation and Interpretation. (2020) (21)
- Estimating Treatment Effect With Clinical Interpretation From a Comparative Clinical Trial With an End Point Subject to Competing Risks (2018) (19)
- Pembrolizumab plus Chemotherapy in Lung Cancer. (2018) (19)
- Predicting future responses based on possibly mis-specified working models (2008) (19)
- Prediction of survival probability based on a linear regression model (1992) (18)
- Interim analyses based on median survival times (1994) (18)
- Quantification of Long-term Survival Benefit in a Comparative Oncology Clinical Study (2018) (16)
- Estimating Subject‐Specific Dependent Competing Risk Profile with Censored Event Time Observations (2011) (12)
- Rank estimation of treatment differences based on repeated measurements subject to dependent censoring (1999) (12)
- Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab as a Result of Adverse Events Lived Significantly Longer Than Patients Who Continued Treatment. (2018) (12)
- Analysis of Response Data for Assessing Treatment Effects in Comparative Clinical Studies (2020) (12)
- Moving beyond our comfort zone. (2013) (11)
- Practical Recommendations on Quantifying and Interpreting Treatment Effects in the Presence of Terminal Competing Risks: A Review. (2021) (10)
- Comparing Risk Scoring Systems Beyond the ROC Paradigm in Survival Analysis (2009) (10)
- Estimating Treatment Effect as the Primary Analysis in a Comparative Study: Moving Beyond P Value. (2020) (10)
- The Optimal Confidence Region for a Random Parameter (2005) (10)
- Selecting appropriate endpoints for assessing treatment effects in comparative clinical studies for COVID-19 (2020) (9)
- Newborn Screening for Cystic Fibrosis Is Complicated by Age-Related Decline in Immunoreactive Trypsinogen Levels (1990) (9)
- Quantifying the totality of treatment effect with multiple event‐time observations in the presence of a terminal event from a comparative clinical study (2018) (9)
- Quantifying the benefit of non-small-cell lung cancer immunotherapy (2019) (8)
- Estimating Subject-Specific Treatment Differences for Risk-Benefit Assessment with Competing Risk Event-Time Data (2011) (8)
- Statistical Inference for Infinite Dimensional Parameters Via Asymptotically Pivotal Estimating Functions (2004) (8)
- The Myth of Making Inferences for an Overall Treatment Efficacy with Data from Multiple Comparative Studies Via Meta-Analysis (2017) (8)
- Assessment of Treatment Effect With Multiple Outcomes in 2 Clinical Trials of Patients With Duchenne Muscular Dystrophy. (2020) (8)
- Analytical issues regarding rosiglitazone meta-analysis. (2011) (7)
- Stratifying Subjects for Treatment Selection with Censored Event Time Data from a Comparative Study (2010) (7)
- Overall survival (OS) with oral selinexor plus low dose dexamethasone (Sd) in patients with triple class refractory-multiple myeloma (TCR-MM). (2019) (7)
- Choosing clinically interpretable summary measures and robust analytic procedures for quantifying the treatment difference in comparative clinical studies (2021) (7)
- Sex as a predictor of response to cancer immunotherapy. (2018) (7)
- Distribution-Free Methods of Estimating Location Difference with Censored Paired Data (1985) (7)
- Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases (2019) (6)
- Restricted mean survival time for the analysis of cardiovascular outcome trials assessing non-inferiority: Case studies from antihyperglycemic drug development. (2019) (6)
- Demonstrating Noninferiority of Accelerated Radiotherapy With Panitumumab vs Standard Radiotherapy With Cisplatin in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma. (2017) (6)
- Implementation Of Estimating-Function Based Inference Procedures With MCMC Sampler (2005) (5)
- Neratinib after trastuzumab in patients with HER2-positive breast cancer. (2016) (5)
- Interpreting Clinical Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer (BRPC). (2018) (5)
- Intensive versus standard blood pressure control in type 2 diabetes: a restricted mean survival time analysis of a randomised controlled trial (2021) (5)
- Pitfall in the Design and Analysis of Comparative Oncology Trials With a Time-to-Event Endpoint and Recommendations (2022) (5)
- Pravastatin for Primary Prevention in Older Adults: Restricted Mean Survival Time Analysis (2018) (5)
- Interpreting the Survival Benefit From Neoadjuvant Chemoradiotherapy Before Surgery for Locally Advanced Squamous Cell Carcinoma of the Esophagus. (2019) (4)
- Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes (2019) (4)
- Classical Model Selection (2013) (4)
- Effects of bracing in adolescents with idiopathic scoliosis. (2014) (4)
- How to Summarize the Safety Profile of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy? (2016) (4)
- Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma (2020) (4)
- Evaluating Noninferiority With Clinically Interpretable Statistics for the PROSELICA Study to Assess Treatment Efficacy of a Reduced Dose of Cabazitaxel for Treating Metastatic Prostate Cancer. (2018) (4)
- On the Restricted Mean Event Time in Survival Analysis (2013) (4)
- Defining Study Outcomes That Better Reflect Individual Response to Treatment (2017) (4)
- Using controlled and real-world data in concert to assess survival benefits in pulmonary arterial hypertension: Insights from SERAPHIN and REVEAL (2017) (3)
- Restricted mean survival time versus conventional measures for treatment decision‐making (2021) (3)
- Simultaneous and Exact Interval Estimates for the Contrast of Two Groups Based on an Extremely High Dimensional Response Variable: Application to Mass Spec Data Analysis (2005) (3)
- Axillary vs Sentinel Lymph Node Dissection in Women With Invasive Breast Cancer. (2018) (3)
- The Highest Confidence Density Region and Its Usage for Inferences about the Survival Function with Censored Data (2008) (3)
- Utility of Restricted Mean Survival Time for Analyzing Time to Nursing Home Placement Among Patients With Dementia (2021) (3)
- Evaluating longitudinal therapy effects via the North Star Ambulatory Assessment (2021) (3)
- Effectively Combining Independent 2 x 2 Tables for Valid Inferences in Meta Analysis with all Available Data but no Artificial Continuity Corrections for Studies with Zero Events and its Application to the Analysis of Rosiglitazone's Cardiovascular Disease Related Event Data (2007) (3)
- Survival Analysis of Treatment Efficacy in Comparative Coronavirus Disease 2019 Studies (2020) (3)
- Meta-analysis to Evaluate High-Dose Therapy Followed by Stem Cell Transplant in Patients With Multiple Myeloma. (2018) (2)
- Defibrotide (DF) for the Treatment of Veno-Occlusive Disease (VOD) and Multi-System Organ Failure (MOF) Post SCT: Analysis of Response and Survival According to Degree and Type of MOF. (2005) (2)
- Gene Expression-Guided Adjuvant Chemotherapy in Breast Cancer. (2018) (2)
- Biodegradable-polymer stents versus durable-polymer stents (2019) (2)
- Trifluridine/tipiracil in metastatic gastric cancer. (2019) (2)
- Estimating and Interpreting the Overall Survival Benefit of Checkpoint Inhibitors via Meta-analysis. (2018) (2)
- Assessing Metronomic Chemotherapy for Progressive Pediatric Solid Malignant Tumors. (2018) (2)
- Discussion of joint modeling longitudinal and survival data (2004) (2)
- Zoledronic Acid Dosing in Patients With Metastatic Breast Cancer. (2017) (2)
- Further clinical interpretation and implications of KEYNOTE-048 findings (2020) (2)
- Regional Hyperthermia With Neoadjuvant Chemotherapy for Treatment of Soft Tissue Sarcoma. (2019) (2)
- Overall Survival in the Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer. (2017) (2)
- Impact of Acute Serum Creatinine Elevation in Patients Treated with Nesiritide (2009) (2)
- Trastuzumab Therapy for 9 Weeks vs 1 Year for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. (2019) (2)
- Progression-free survival in the ICON8 trial (2020) (2)
- Combining Association Tests across Multiple Genetic Markers in Case-Control Studies (2007) (2)
- Appropriate Analysis of Duration of Response Data in Cancer Trials. (2020) (2)
- A Shorter Regimen for Rifampin-Resistant Tuberculosis. (2019) (2)
- Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer. (2020) (1)
- Interpreting Clinical Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer (BRPC) (2018) (1)
- Interpreting the Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma. (2018) (1)
- Analysis of Incomplete Repeated Measurements with Dependent Follow-up Times (1998) (1)
- Issues in genomic screening: Critical values, sample sizes, and the ability to detect linkage (1999) (1)
- Fulvestrant plus capivasertib for metastatic breast cancer. (2020) (1)
- Estimating Subject-Specific Treatment Differences for Risk-Benefit Assessment with Applications to Beta-Blocker Effectiveness Trials (2013) (1)
- Risk-Benefit Comparisons Between Shorter and Longer Durations of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer. (2020) (1)
- Preservation of Function over time as Measured by North Star Ambulatory Assessment in Ambulatory Boys with Nonsense Mutation Muscular Dystrophy Treated with Ataluren (S51.004) (2019) (1)
- Predicting the Future Subject's Outcome via an Optimal Stratification Procedure with Baseline Information (2014) (1)
- Interpreting the Benefit of Trifluridine/Tipiracil in Metastatic Colorectal Cancer With Respect to Progression-Free Survival and Overall Survival. (2018) (1)
- Unifying Design and Analysis for Superiority and Noninferiority Trials With Appropriate End Point. (2019) (1)
- Quantifying Immunoscore performance (2018) (1)
- Quantifying Treatment Effects in Trials with Multiple Event-Time Outcomes (2022) (1)
- Identifying patients who need additional biomarkers for better prediction of health outcome or diagnosis of clinical phenotype (2007) (1)
- Effects of Aspirin in the Healthy Elderly. (2019) (0)
- Wei‐Lin‐Weissfeld Method for Multiple Times to Events (2008) (0)
- Palbociclib and Fulvestrant in Breast Cancer. (2019) (0)
- Quantifying the Effect of Lower vs Higher Positive End-Expiratory Pressure on Ventilator-Free Survival in ICU Patients. (2021) (0)
- Moving beyond conventional stratified analysis to assess the treatment effect in a comparative oncology study (2021) (0)
- Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis for Low Rectal Cancers. (2020) (0)
- REPLICATION TRIAL TO CONFIRM REVERSAL OF COGNITIVE DECLINE WITH BRYOSTATIN FOR ADVANCED ALZHEIMER’S PATIENTS IN THE ABSENCE OF MEMANTINE (2019) (0)
- Body Composition and Overall Survival in Patients With Nonmetastatic Breast Cancer. (2019) (0)
- Letter by McCaw et al Regarding Article, "The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease". (2021) (0)
- Safety Study of Salmeterol in Asthma in Adults. (2016) (0)
- Restricted Mean Survival Time for Analysis and Interpretation of Clinical Trials for Heart Failure Devices (2020) (0)
- Quantifying Clinical Utility of Enzalutamide for Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer. (2022) (0)
- Questions About a Risk Prediction Model of Mortality After Esophagectomy for Cancer. (2021) (0)
- Intensive Versus Standard Blood Pressure Lowering and Days Free of Cardiovascular Events and Serious Adverse Events: a Post Hoc Analysis of Systolic Blood Pressure Intervention Trial (2022) (0)
- Interpreting the Prognostic Value of Unrecognized Myocardial Infarction Among Older Adults. (2019) (0)
- Handling Informative Premature Treatment or Study Discontinuation for Assessing Between-Group Differences in a Comparative Oncology Trial. (2022) (0)
- Assessing the Prognostic Value of the Automated Bone Scan Index for Prostate Cancer. (2019) (0)
- Evaluating Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma. (2022) (0)
- One- and Two-Sample Nonparametric Inference Procedures in the Presence of Dependent Censoring (2004) (0)
- Quantifying the Treatment Effect of Drug-Eluting Stents Optimized for Biocompatibility vs Bare-Metal Stents With a Single Month of Dual Antiplatelet Therapy. (2019) (0)
- Restricted Mean Survival Time in Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure (2020) (0)
- SIGNIFICANT COGNITIVE IMPROVEMENT WITH BRYOSTATIN FOR ADVANCED ALZHEIMER’S PATIENTS IN THE ABSENCE OF MEMANTINE (2018) (0)
- P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. (2019) (0)
- Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older. (2020) (0)
- Using Confidence Intervals to Quantify Statistical and Clinical Evidence for the Treatment Effect in a Comparative Study-Moving Beyond P Values. (2019) (0)
- Comparing Short- and Long-Term Treatment Duration of Bevacizumab for Advanced Ovarian Cancer. (2023) (0)
- Analysis of Outcomes With Addition of Immunotherapy to Chemoradiation Therapy for Non-Small Cell Lung Cancer. (2021) (0)
- Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy and Survival of Patients With Low-Risk Nasopharyngeal Carcinoma. (2023) (0)
- Assessing the Clinical Utility of Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer. (2022) (0)
- Clinical Utility Assessment of Gonadotropin-Releasing Hormone Analogs Among Women Younger Than 35 Years. (2022) (0)
- Pembrolizumab in Triple-Negative Breast Cancer. (2022) (0)
- Quantifying and Interpreting Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Cancer Control for Advanced Gastroesophageal Cancer Among an Older Population. (2021) (0)
- Analysis of Long-term Benefits of Intensive Blood Pressure Control. (2019) (0)
- Quantifying and Interpreting the Prediction Accuracy of Models for the Time of a Cardiovascular Event-Moving Beyond C Statistic: A Review. (2023) (0)
- Quantifying the Long-term Survival Benefit of Pembrolizumab for Patients With Advanced Gastric Cancer. (2021) (0)
- Evaluating Treatment Effect of Transcatheter Interatrial Shunt Device Using Heart Failure Event Rates. (2019) (0)
- Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer. (2016) (0)
- Quantifying the Added Value of Low-Molecular-Weight Heparin to Intermittent Pneumatic Compression for Preventing Venous Thromboembolic Events Under the Risk-Benefit Perspective. (2019) (0)
- Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Trial. (2023) (0)
- Assessing the prognostic impact of intermediate outcomes on survival time in relapsed/refractory multiple myeloma (RRMM) patients (pts) via a robust and clinically interpretable quantitative procedure. (2015) (0)
- Restricted mean survival time analysis in heart failure clinical trials (2020) (0)
- Quantifying Clinical Utility of Adjuvant Abemaciclib in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy. (2022) (0)
- The Myth of Making Inferences for an Overall Treatment Efficacy with Data from Multiple Comparative Studies Via Meta-Analysis (2017) (0)
- Olaparib in Metastatic Castration-Resistant Prostate Cancer. (2021) (0)
- Interpreting the Long-term Prognostic Value of Total Mesorectal Excision Plane Quality in Rectal Adenocarcinoma. (2019) (0)
This paper list is powered by the following services:
Other Resources About Lee-Jen Wei
What Schools Are Affiliated With Lee-Jen Wei?
Lee-Jen Wei is affiliated with the following schools:
